Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. vaccine live
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Vaccine Live Articles & Analysis

27 news found

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA vaccine, DNA vaccine, live-attenuated vaccine, virus-like particle vaccine, protein subunit vaccine, and many other custom vaccines. Protheragen’s ...

ByProtheragen


Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development

Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early ...

ByCreative Diagnostics


Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics

Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics

As they were passing by the R&D facilities, Bernard Sagaert, interim Chief Executive Officer of etherna, explained how the project is benefiting from etherna’s technologies, at multiple levels and stages: “We are delighted to partner with Univercells and Afrigen Biologics on this important project by providing expert support and knowhow in all the key areas of mRNA ...

ByeTheRNA


Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines

Micron Biomedical Presents at the White House Summit on the Future of COVID-19 Vaccines

Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. ...

ByMicron Biomedical, Inc.


FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

FDA Accepts Dupixent (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

For people with EoE, swallowing the smallest amount of food can be a painful and worrisome choking experience. Those with EoE live with anxiety and frustration from having a constantly evolving list of foods to avoid. ...

ByRegeneron Pharmaceuticals Inc.


Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

Dupixent (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

We also remain committed to investigating Dupixent in other conditions where type 2 inflammation may significantly impact patients' lives, including eosinophilic esophagitis, prurigo nodularis and chronic spontaneous urticaria." ...

ByRegeneron Pharmaceuticals Inc.


NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

VAXIMM’s plug and play DNA vaccination technology is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target a wide range of cancer-related antigens. The platform allows for fast and scalable manufacturing of personalized T-cell cancer ...

ByNEC OncoImmunity AS 


< Back to Home  Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors

< Back to Home Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors

We are excited to work with Wacker Biotech given their significant experience manufacturing GMP-compliant, live microbial products in a closed production system," said Christopher Thanos, PhD, Actym's President and Chief Executive Officer. ...

ByActym Therapeutics


Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...

ByBristol Myers Squibb Corporate


COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). ...

ByOcugen, Inc.


Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

The World Health Organization (WHO) recently added COVAXIN™ (BBV152) to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™ (BBV152). ...

ByOcugen, Inc.


New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using COVAXIN™. ...

ByOcugen, Inc.


Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug application (IND) to initiate a first-in-human clinical trial of OCU400 ...

ByOcugen, Inc.


Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152)

Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152)

The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN™. ...

ByOcugen, Inc.


MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine

The potential of microbial therapy is evident in probiotics and live bacteria preventive vaccines and the recent use of fecal microbiota transplantation to improve human health or cure certain diseases. In addition, microorganisms can be designed as living therapies to perform specific functions in the human body. Benefits may include preventing ...

ByCD Genomics


Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Preclinical Data on Intranasal COVID-19 Vaccine Shows Protection from SARS-CoV-2 after Single Dose

Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern ? ...

ByMeissa Vaccines, Inc.


Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

Since the discovery of RSV in 1956, no vaccine has been approved for prevention. “We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissa’s AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine ...

ByMeissa Vaccines, Inc.


Enesi Pharma’s ImplaVax-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

Enesi Pharma’s ImplaVax-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose ...

ByEnesi Pharma Limited


Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella

Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines ...

ByEnesi Pharma Limited


Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit ...

ByCreative Biolabs

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT